Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban

Translated title of the contribution: Soluble syndecan-1 levels in different plasma cell dyscrasias

Judit Jánosi, Anna Sebestyén, Gábor Mikala, Mónika Petö, János Jákó, Gyula Domján, Júlia Németh, Zoltán Kis, László Kopper, István Vályi-Nagy

Research output: Contribution to journalArticle

2 Citations (Scopus)


Introduction: Syndecans are a family of cell surface proteoglycans. In the bone marrow of multiple myeloma patients syndecan-1 is expressed only on the surface of malignant plasma cells. The aim of the study was to determine the soluble syndecan-1 levels in different plasma cell dyscrasias. Methods: The serum concentration of soluble syndecan-1 was measured using human syndecan-1 enzyme-linked immunosorbent assay kit. Results: Patients with multiple myeloma showed a significantly higher median serum syndecan-1 level than patients with plasmocytoma or monoclonal gammopathy of undetermined significance. Statistically significant differences were also observed among Salmon-Durie subgroups of 50 patients suffering from multiple myeloma. In addition to these findings a statistical correlation with other independent prognostic factors such as serum beta2-microglobulin level, monoclonal immunoglobulin concentration, and bone marrow plasma cell count could also be noted. A significant decrease in median serum syndecan level was observed in patients who responded to chemotherapy, whereas no change in the median syndecan-1 level could be observed in nonresponders. Conclusion: These findings confirm the observation that high serum soluble syndecan-1 level is associated with a more advanced disease stage and is a strong independent indicator of poor prognosis. A diminished serum syndecan-1 reading as a result of chemotherapy may be a good indicator of favorable response to antitumor treatment.

Translated title of the contributionSoluble syndecan-1 levels in different plasma cell dyscrasias
Original languageHungarian
Pages (from-to)165-168
Number of pages4
JournalOrvosi hetilap
Issue number4
Publication statusPublished - Dec 1 2005

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Soluble syndecan-1 levels in different plasma cell dyscrasias'. Together they form a unique fingerprint.

  • Cite this

    Jánosi, J., Sebestyén, A., Mikala, G., Petö, M., Jákó, J., Domján, G., Németh, J., Kis, Z., Kopper, L., & Vályi-Nagy, I. (2005). Szolúbilis syndecan-1- (CD 138)-koncentráció plazmasejt-dyscrasiákban. Orvosi hetilap, 146(4), 165-168.